1. Search Result
Search Result
Results for "

240

" in MedChemExpress (MCE) Product Catalog:

85

Inhibitors & Agonists

1

Screening Libraries

3

Biochemical Assay Reagents

1

Peptides

3

Inhibitory Antibodies

5

Natural
Products

5

Recombinant Proteins

11

Isotope-Labeled Compounds

6

Antibodies

3

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-W193545A
    ERG240
    3 Publications Verification

    Others Inflammation/Immunology Cancer
    ERG240 is an oral active branched-chain amino acid aminotransferase 1 (BCAT1) inhibitor. ERG240 can be used for the research of cancer, rheumatoid arthritis, and bone disease .
    ERG240
  • HY-138622

    Liposome Others
    24:0 Lyso PC is a lysophospholipid (LyP). 24:0 Lyso PC could be used for mRNA drug delivery .
    24:0 Lyso PC
  • HY-138622S1

    Isotope-Labeled Compounds Others
    24:0 Lyso PC-d44 is the deuterium labeled 24:0 Lyso PC. 24:0 Lyso PC is a lysophospholipid (LyP). 24:0 Lyso PC could be used for mRNA drug delivery .
    24:0 Lyso PC-d4
  • HY-138622S

    Isotope-Labeled Compounds Others
    24:0 Lyso PC- 13C6 is the 13C labeled 24:0 Lyso PC. 24:0 Lyso PC is a lysophospholipid (LyP). 24:0 Lyso PC could be used for mRNA drug delivery .
    24:0 Lyso PC-13C6
  • HY-19795R

    p97 Cancer
    ML240 (Standard) is the analytical standard of ML240. This product is intended for research and analytical applications. ML240 is a potent p97 inhibitor, inhibiting p97 ATPase with IC50 value of 100 nM.
    ML240 (Standard)
  • HY-163984

    Bacterial Infection
    Antibacterial agent 240 (compound 62-7c) is an antibacterial agent that can target multidrug-resistant (MDR) MRSA strains. Antibacterial agent 240 showed high biosafety and potent anti-infection activity in mouse pneumonia and mouse wound models of MRSA infection .
    Antibacterial agent 240
  • HY-161845

    Drug Derivative Cancer
    Anticancer agent 240 (compound 9b) is an 8-quinolinesulfonamide derivative with a cytotoxicity activity. Anticancer agent 240 shows inhibitory activity in Caco-2, SNB-19, A-549, and SKOV-3 cell line IC50 values of 0.26, 0.38, 0.40 and 4.16 μM .
    Anticancer agent 240
  • HY-P10295

    MDM-2/p53 Cancer
    p53 (232-240) is a peptide segment of the 232-240 amino acid sequence of the human tumor suppressor protein p53. p53 (232-240) enhances its binding affinity to the Major histocompatibility complex (MHC), thereby enhancing the immunogenicity of this peptide to enhance the immune system's response to tumor antigens. p53 (232-240) can be used in the development of cancer vaccines and in the study of tumor cell recognition and clearance by the immune system .
    p53 (232-240)
  • HY-115823

    Potassium Channel Neurological Disease
    ztz240 is a chemical modulator of voltage-gated potassium channel Kv7 (KCNQ) (KCNQ2 and 3: EC50=6.1 μM; KCNQ4: EC50=12.2 μM). ztz240 can be used in analgesia and anti-epileptic research .
    ztz240
  • HY-146927S

    Isotope-Labeled Compounds Others
    24:0 Coenzyme A-d4 is deuterium labeled 24:0 Coenzyme A.
    24:0 Coenzyme A-d4
  • HY-146943S

    Isotope-Labeled Compounds Others
    24:0 L-carnitine-d4 is deuterium labeled 24:0 L-carnitine.
    24:0 L-carnitine-d4
  • HY-19795
    ML240
    4 Publications Verification

    p97 Cancer
    ML240 is a potent p97 inhibitor, inhibiting p97 ATPase with IC50 value of 100 nM.
    ML240
  • HY-173623

    iGluR Neurological Disease
    EU 1622-240 is a biased positive allosteric modulator of GluN2B, GluN2C, and GluN2D, with EC50s of 0.57, 0.82, 1.1 μM respectively. EU 1622-240 has good physicochemical properties, in vitro stability, and permeability .
    EU 1622-240
  • HY-RS14707

    Small Interfering RNA (siRNA) Others

    TMEM240 Human Pre-designed siRNA Set A contains three designed siRNAs for TMEM240 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    TMEM240 Human Pre-designed siRNA Set A
    TMEM240 Human Pre-designed siRNA Set A
  • HY-E70257

    Lignoceroyl coenzyme A triammonium

    Drug Intermediate Others
    24:0 Coenzyme A (Lignoceroyl coenzyme A triammonium) is an intermediate in the synthesis of hydroxyceramide .
    24:0 Coenzyme A
  • HY-150350

    Biochemical Assay Reagents Others
    20mM HEPES, 150 mM NaCl, 240mM Sucrose, pH 7.2 buffer is a commonly used antibody storage buffer.
    20mM HEPES, 150 mM NaCl, 240mM Sucrose, pH 7.2 buffer
  • HY-P2974
    Elastase, Porcine pancreas
    1 Publications Verification

    EC 3.4.21.36; Pancreatopeptidase E

    Elastase Metabolic Disease
    Elastase, Porcine pancreas (EC 3.4.21.36) is a single polypeptide chain of 240 amino acid residues, derived from pig pancreas. Elastase, Porcine pancreas is a serine protease that can hydrolyze proteins and polypeptide. Elastase from porcine pancreas can induce emphysema in hamsters .
    Elastase, Porcine pancreas
  • HY-109106A

    SK-1403; AJT240; PLS240

    CaSR Endocrinology
    Upacicalcet sodium is a non-peptide calcimimetic that acts as a CaSR agonist (EC50 = 10.8 nM). Upacicalcet sodium reduces serum intact parathyroid hormone (iPTH) and serum Ca2+ levels, reducing hypocalcemia and gastrointestinal complications. Upacicalcet sodium sodium improves vascular calcification and bone disorders in the Adenine (HY-B0152)-induced secondary hyperparathyroidism (SHPT) rat model. Upacicalcet sodium sodium inhibits cortical pore formation and reduces bone fibrosis in rats with chronic kidney disease (CKD). Upacicalcet sodium is useful for studying SHPT .
    Upacicalcet sodium
  • HY-109106

    SK-1403 free acid; AJT240 free acid; PLS240 free acid

    CaSR Endocrinology
    Upacicalcet is a non-peptide calcimimetic that acts as a CaSR agonist (EC50 = 10.8 nM). Upacicalcet reduces serum intact parathyroid hormone (iPTH) and serum Ca2+ levels, reducing hypocalcemia and gastrointestinal complications. Upacicalcet improves vascular calcification and bone disorders in the Adenine (HY-B0152)-induced secondary hyperparathyroidism (SHPT) rat model. Upacicalcet inhibits cortical pore formation and reduces bone fibrosis in rats with chronic kidney disease (CKD). Upacicalcet is useful for studying SHPT .
    Upacicalcet
  • HY-109106B

    (Rac)-SK-1403 free acid; (Rac)-AJT240 free acid; (Rac)-PLS240 free acid

    CaSR Endocrinology
    (Rac)-Upacicalcet is the racemate of Upacicalcet (HY-109106). Upacicalcet is a non-peptide calcimimetic that acts as a CaSR agonist (EC50 = 10.8 nM). Upacicalcet reduces serum intact parathyroid hormone (iPTH) and serum Ca2+ levels, reducing hypocalcemia and gastrointestinal complications. Upacicalcet improves vascular calcification and bone disorders in the Adenine (HY-B0152)-induced secondary hyperparathyroidism (SHPT) rat model. Upacicalcet inhibits cortical pore formation and reduces bone fibrosis in rats with chronic kidney disease (CKD). Upacicalcet is useful for studying SHPT .
    (Rac)-Upacicalcet
  • HY-10337
    Brivanib
    3 Publications Verification

    BMS-540215

    VEGFR Autophagy Cancer
    Brivanib (BMS-540215) is an ATP-competitive inhibitor against VEGFR2 with an IC50 of 25 nM, and has moderate potency against VEGFR-1 and FGFR-1, but >240-fold against PDGFR-β .
    Brivanib
  • HY-10336
    Brivanib (alaninate)
    3 Publications Verification

    BMS-582664

    VEGFR Autophagy Cancer
    Brivanib alaninate (BMS-582664) is an ATP-competitive inhibitor against VEGFR2 with an IC50 of 25 nM; has moderate potency against VEGFR-1 and FGFR-1, but more than 240-fold against PDGFRβ .
    Brivanib (alaninate)
  • HY-172665

    Biochemical Assay Reagents Metabolic Disease
    C24 Ceramide (d18:1(14Z)/24:0) is a ceramide. C24 Ceramide (d18:1(14Z)/24:0) can be used in the research of obesity .
    C24 Ceramide (d18:1(14Z)/24:0)
  • HY-10337R

    BMS-540215 (Standard)

    Reference Standards VEGFR Autophagy Cancer
    Brivanib (Standard) is the analytical standard of Brivanib. This product is intended for research and analytical applications. Brivanib (BMS-540215) is an ATP-competitive inhibitor against VEGFR2 with an IC50 of 25 nM, and has moderate potency against VEGFR-1 and FGFR-1, but >240-fold against PDGFR-β .
    Brivanib (Standard)
  • HY-10336R

    BMS-582664 (Standard)

    Reference Standards VEGFR Autophagy Cancer
    Brivanib (alaninate) (Standard) is the analytical standard of Brivanib (alaninate). This product is intended for research and analytical applications. Brivanib alaninate (BMS-582664) is an ATP-competitive inhibitor against VEGFR2 with an IC50 of 25 nM; has moderate potency against VEGFR-1 and FGFR-1, but more than 240-fold against PDGFRβ .
    Brivanib (alaninate) (Standard)
  • HY-W758126

    Isotope-Labeled Compounds Others
    (R)-Brivanib alaninate-d4 is the deuterium-labeled Brivanib (alaninate) (HY-10336). Brivanib alaninate (BMS-582664) is an ATP-competitive inhibitor against VEGFR2 with an IC50 of 25 nM; has moderate potency against VEGFR-1 and FGFR-1, but more than 240-fold against PDGFRβ .
    (R)-Brivanib alaninate-d4
  • HY-171368

    Biochemical Assay Reagents Others
    L-Histidine buffer, Sterile is a commonly used antibody storage buffer with a formula of 20 mM L-Histidine, 240 mM Sucrose, pH 5.8.
    L-Histidine buffer,Sterile
  • HY-139694

    Adenosine Receptor Others
    hA3AR agonist 1 is a potent human A3 adenosine receptor (hA3AR) agonist with a Ki value of 2.40 nM.
    hA3AR agonist 1
  • HY-111578
    BDP-13176
    1 Publications Verification

    Arp2/3 Complex Cancer
    BDP-13176 is a potent fascin 1 inhibitor, with a Kd of 90 nM and an IC50 of 240 nM. BDP-13176 has potential as an anti-metastatic agent .
    BDP-13176
  • HY-RS00620

    Small Interfering RNA (siRNA) Others

    ALOX5 Human Pre-designed siRNA Set A contains three designed siRNAs for ALOX5 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    ALOX5 Human Pre-designed siRNA Set A
    ALOX5 Human Pre-designed siRNA Set A
  • HY-16900
    Rolipram
    Maximum Cited Publications
    15 Publications Verification

    (R,S)-Rolipram; (±)-Rolipram; ZK 62711

    Phosphodiesterase (PDE) Bacterial HIV Neurological Disease Cancer
    Rolipram is a selective phosphodiesterases PDE4 inhibitor with IC50s of 3 nM, 130 nM and 240 nM for PDE4A, PDE4B, and PDE4D, respectively.
    Rolipram
  • HY-112355

    Aurora Kinase Cancer
    Aurora kinase inhibitor-2 is a selective and ATP-competitive Aurora kinase inhibitor with IC50s of 310 nM and 240 nM for Aurora A and Aurora B, respectively .
    Aurora kinase inhibitor-2
  • HY-156255

    Monoamine Oxidase Neurological Disease
    MAO-B-IN-25 (compound 92) is a selective MAO-B inhibitor with IC50s of 0.5 nM and 240 nM for MAO-A and MAO-B, respectively .
    MAO-B-IN-25
  • HY-16900A
    (R)-(-)-Rolipram
    2 Publications Verification

    (R)-Rolipram; (-)-Rolipram

    Phosphodiesterase (PDE) Neurological Disease
    (R)-(-)-Rolipram is the R-enantiomer of Rolipram. Rolipram is a selective inhibitor of phosphodiesterases PDE4 with IC50 of 3 nM, 130 nM and 240 nM for PDE4A, PDE4B, and PDE4D, respectively.
    (R)-(-)-Rolipram
  • HY-103366

    Checkpoint Kinase (Chk) Cancer
    NSC 109555 ditosylate is a potent, selective, ATP-competitive checkpoint kinase 2 (Chk2) inhibitor with an IC50 of 240 nM. NSC 109555 ditosylate can be used for the research of cancer .
    NSC 109555 ditosylate
  • HY-173050

    Parasite Infection
    NEU-1017 is a broad-spectrum antiparasitic agent. NEU-1017 inhibits T. brucei, L. major, and P. falciparum with EC50 values of 210 nM, 240 nM, and 3 nM, respectively . X
    NEU-1017
  • HY-N15451

    Pyruvate Kinase Infection
    Deoxytopsentin is a compound that can be found in marine sponges. It is an inhibitor of pyruvate kinase (PK) in methicillin-resistant Staphylococcus aureus (MRSA), with an IC50 value of 240 nM. Deoxytopsentin can be used in research in the field of anti-infection .
    Deoxytopsentin
  • HY-139289
    ART812
    1 Publications Verification

    DNA/RNA Synthesis Cancer
    ART812 is an orally active DNA polymerase Polθ inhibitor with an IC50 value of 7.6 nM. ART812 has an IC50 value of 240 nM for cell based microhomology-mediated end joining (MMEJ) .
    ART812
  • HY-100911

    Calmodulin Neurological Disease
    W-5 hydrochloride is a calmodulin antagonist. W-5 hydrochloride inhibits phosphodiesterase activation with an IC50 value of 240 µM. W-5 hydrochloride can be used as a negative control for W-7 (HY-100912) .
    W-5 hydrochloride
  • HY-121883
    Lignoceric acid
    1 Publications Verification

    Tetracosanoic acid

    Endogenous Metabolite Neurological Disease
    Lignoceric acid (Tetracosanoic acid) is a 24-carbon saturated (24:0) fatty acid, which is synthesized in the developing brain. Lignoceric acid is also a by-product of lignin production. Lignoceric acid can be used for Zellweger cerebro‐hepato‐renal syndrome and adrenoleukodystrophy research .
    Lignoceric acid
  • HY-16900R

    (R,S)-Rolipram (Standard); (±)-Rolipram (Standard); ZK 62711 (Standard)

    Reference Standards Phosphodiesterase (PDE) Bacterial HIV Neurological Disease Cancer
    Rolipram (Standard) is the analytical standard of Rolipram. This product is intended for research and analytical applications. Rolipram is a selective phosphodiesterases PDE4 inhibitor with IC50s of 3 nM, 130 nM and 240 nM for PDE4A, PDE4B, and PDE4D, respectively.
    Rolipram (Standard)
  • HY-135265

    Ro 12-5637

    Monoamine Oxidase Neurological Disease
    Moclobemide N-Oxide (Ro 12-5637) is N-oxide metabolite of Moclobemide. Moclobemide N-Oxide retains certain MAO-A (monoamine oxidase) inhibitory activity, but is generally present in low concentrations. Moclobemide N-Oxide can be detected by UV absorption at 240 nm .
    Moclobemide N-Oxide
  • HY-12550

    Potassium Channel Neurological Disease
    GW542573X is a potent and selective Ca 2+-activated K + 2 (SK2) channels activator. GW542573X induces the Ca 2+-response curve of hSK1 that left-shifted from an EC50 (Ca 2+) value of 410 nM to 240 nM .
    GW542573X
  • HY-126236
    3,5-Diiodothyropropionic acid
    1 Publications Verification

    Thyroid Hormone Receptor Cardiovascular Disease Endocrinology
    3,5-Diiodothyropropionic acid is a thyroid hormone analog, induces α-myosin heavy chain mRNA expression, binds to thyroid hormone receptor (TR), with Ka of 2.40 and 4.06 M -1 for TRα1 and TRβ1, respectively .
    3,5-Diiodothyropropionic acid
  • HY-121883S

    Tetracosanoic acid-d47

    Isotope-Labeled Compounds Endogenous Metabolite Neurological Disease
    Lignoceric acid-d47 is the deuterium labeled Lignoceric acid. Lignoceric acid (Tetracosanoic acid) is a 24-carbon saturated (24:0) fatty acid, which is synthesized in the developing brain. Lignoceric acid is also a by-product of lignin production. Lignoceric acid can be used for Zellweger cerebro‐hepato‐renal syndrome and adrenoleukodystrophy research .
    Lignoceric acid-d47
  • HY-121883SS5

    Endogenous Metabolite Neurological Disease
    Lignoceric acid-d9 is the deuterium labeled Lignoceric acid. Lignoceric acid (Tetracosanoic acid) is a 24-carbon saturated (24:0) fatty acid, which is synthesized in the developing brain. Lignoceric acid is also a by-product of lignin production. Lignoceric acid can be used for Zellweger cerebro‐hepato‐renal syndrome and adrenoleukodystrophy research .
    Lignoceric acid-d9
  • HY-W013852

    Ser/Thr Kinase Tyrosinase PKA PKC EGFR Cancer
    PKC-IN-6 (Compound 21) is a selective inhibitor of tyrosine and serine kinases. PKC-IN-6 shows inhibitory activity against PKC-α, PKC-δ, PKA, EGF-R with IC50 values of 240, >500, >500, >100 μM, respectively. PKC-IN-6 is promising for research of cancers .
    PKC-IN-6
  • HY-121883S4

    Tetracosanoic acid-d4-2

    Endogenous Metabolite Neurological Disease
    Lignoceric acid-d4-2 is the deuterium labeled Lignoceric acid. Lignoceric acid (Tetracosanoic acid) is a 24-carbon saturated (24:0) fatty acid, which is synthesized in the developing brain. Lignoceric acid is also a by-product of lignin production. Lignoceric acid can be used for Zellweger cerebro‐hepato‐renal syndrome and adrenoleukodystrophy research .
    Lignoceric acid-d4-2
  • HY-121883S1

    Tetracosanoic acid-d3

    Endogenous Metabolite Neurological Disease
    Lignoceric acid-d3 is the deuterium labeled Lignoceric acid . Lignoceric acid (Tetracosanoic acid) is a 24-carbon saturated (24:0) fatty acid, which is synthesized in the developing brain. Lignoceric acid is also a by-product of lignin production. Lignoceric acid can be used for Zellweger cerebro‐hepato‐renal syndrome and adrenoleukodystrophy research .
    Lignoceric acid-d3
  • HY-149806

    Epigenetic Reader Domain Cancer
    BD-IN-1 is a pan bromodomain (BD) inhibitor with KD values of 250, 420, 130, 430, 67, 240, 970 nM for BRD4(1), CBP, BRPF1B, BRD7, BRD9, BRDT(1), CECR2 respectively. BD-IN-1 shows antiproliferative activity .
    Bromodomain IN-2

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: